Cargando…

Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program

SIMPLE SUMMARY: Leptomeningeal metastases represent an unmet need due to the lack of effective therapy and poor survival. The tyrosine kinase inhibitor, neratinib, has demonstrated promising activity against brain metastases from HER2-positive breast cancer, as reported by the TBCRC and NALA trials,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pellerino, Alessia, Soffietti, Riccardo, Bruno, Francesco, Manna, Roberta, Muscolino, Erminia, Botta, Pierangela, Palmiero, Rosa, Rudà, Roberta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8909342/ https://www.ncbi.nlm.nih.gov/pubmed/35267501 http://dx.doi.org/10.3390/cancers14051192

Ejemplares similares

Leptomeningeal Metastases from Solid Tumors: Recent Advances in Diagnosis and Molecular Approaches
por: Pellerino, Alessia, et al.
Publicado: (2021)

Management of Brain and Leptomeningeal Metastases from Breast Cancer
por: Pellerino, Alessia, et al.
Publicado: (2020)

Clinical Significance of Molecular Alterations and Systemic Therapy for Meningiomas: Where Do We Stand?
por: Pellerino, Alessia, et al.
Publicado: (2022)

Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments
por: Pellerino, Alessia, et al.
Publicado: (2018)

Blood–Brain Barrier in Brain Tumors: Biology and Clinical Relevance
por: Mo, Francesca, et al.
Publicado: (2021)

Ependymoma: Evaluation and Management Updates
por: Rudà, Roberta, et al.
Publicado: (2022)

Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?
por: Pellerino, Alessia, et al.
Publicado: (2023)

Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects
por: Bruno, Francesco, et al.
Publicado: (2022)

Pembrolizumab-Induced Isolated Cranial Neuropathy: A Rare Case Report and Review of Literature
por: Bruno, Francesco, et al.
Publicado: (2021)

Targeted Therapies in Rare Brain Tumours
por: Bruno, Francesco, et al.
Publicado: (2021)

Neurotoxicity from Old and New Radiation Treatments for Brain Tumors
por: Soffietti, Riccardo, et al.
Publicado: (2023)

BSBM-12 STAT3 EXPRESSION IN BRAIN METASTASES FROM BREAST CANCER: CORRELATIONS WITH DIFFERENT MOLECULAR SUBTYPES AND CLINICAL OUTCOME
por: Pellerino, Alessia, et al.
Publicado: (2023)

Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer
por: Ren, Lanqi, et al.
Publicado: (2023)

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases
por: Lazaratos, Anna-Maria, et al.
Publicado: (2023)

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
por: Saura, Cristina, et al.
Publicado: (2020)

Brain Metastasis from Unknown Primary Tumour: Moving from Old Retrospective Studies to Clinical Trials on Targeted Agents
por: Balestrino, Roberta, et al.
Publicado: (2020)

Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis
por: Wu, Yue, et al.
Publicado: (2022)

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
por: Chilà, Giovanna, et al.
Publicado: (2021)

Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens
por: Moy, Beverly, et al.
Publicado: (2021)

Mechanisms and Therapy for Cancer Metastasis to the Brain
por: Franchino, Federica, et al.
Publicado: (2018)

Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast Cancer
por: Saura, Cristina, et al.
Publicado: (2021)

Neratinib for HER2-positive breast cancer with an overlooked option
por: Guo, Liting, et al.
Publicado: (2023)

Elderly Gliobastoma Patients: The Impact of Surgery and Adjuvant Treatments on Survival: A Single Institution Experience
por: Bruno, Francesco, et al.
Publicado: (2022)

Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring
por: Chiavazza, C., et al.
Publicado: (2018)

Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial
por: Hurvitz, Sara A., et al.
Publicado: (2021)

Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib
por: Alkhezayem, Sara, et al.
Publicado: (2020)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Neratinib for the Treatment of Early-Stage HER2-Positive Breast Cancer
por: Miles, Jennifer, et al.
Publicado: (2018)

Neratinib for Extended Anti-HER2 Therapy in Early Breast Cancer
por: Budd, G. Thomas, et al.
Publicado: (2018)

Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer
por: Eli, Lisa D., et al.
Publicado: (2022)

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases
por: Freedman, Rachel A., et al.
Publicado: (2019)

HER2+ esophageal carcinoma leptomeningeal metastases treated with intrathecal trastuzumab regimen
por: Wu, Scott A, et al.
Publicado: (2023)

Newly diagnosed Glioblastoma Multiforme (GBM) during COVID-19 pandemic: changes in therapeutic approach to minimize in-hospital SARS-COV-2 contagion in pre-vaccine era
por: Internò, Valeria, et al.
Publicado: (2022)

Rapid symptomatic relief of HER2-positive gastric cancer leptomeningeal carcinomatosis with lapatinib, trastuzumab and capecitabine: a case report
por: Jiao, Xiao-Dong, et al.
Publicado: (2018)

Neratinib for breast cancer
Publicado: (2019)

NTRK Fusions in Central Nervous System Tumors: A Rare, but Worthy Target
por: Gambella, Alessandro, et al.
Publicado: (2020)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
por: Harding, James J., et al.
Publicado: (2023)

THER-12. PRECLINICAL EVALUATION OF NERATINIB PLUS T-DM1 IN ORTHOTOPIC PDX MODELS OF HER2-POSITIVE BREAST CANCER BRAIN METASTASES
por: Ni, Jing, et al.
Publicado: (2019)

Management of Diarrhea in Patients with HER2-Positive Breast Cancer Treated with Neratinib: A Case Series and Summary of the Literature
por: Kruse, Megan L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5haptn67lkad7qamojr8allhm0